Recruitment

Recruitment Status
Completed
Estimated Enrollment
80

Inclusion Criteria

Patient must be able to give own signed informed consent.
BRAF and/or MEK inhibitors
2nd line treatment for metastatic disease
...
Patient must be able to give own signed informed consent.
BRAF and/or MEK inhibitors
2nd line treatment for metastatic disease
Patients with prior adjuvant treatment are allowed.
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
1st line treatment for metastatic disease
Patients were FFPE and fresh frozen tissue is available (both mandatory).
Adjuvant treatment
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
Patients ≥ 18 years of age.

Summary

Conditions
  • Advanced Melanoma
  • Metastatic Melanoma
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

Patient must be able to give own signed informed consent.
BRAF and/or MEK inhibitors
2nd line treatment for metastatic disease
...
Patient must be able to give own signed informed consent.
BRAF and/or MEK inhibitors
2nd line treatment for metastatic disease
Patients with prior adjuvant treatment are allowed.
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
1st line treatment for metastatic disease
Patients were FFPE and fresh frozen tissue is available (both mandatory).
Adjuvant treatment
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
Patients ≥ 18 years of age.

Tracking Information

NCT #
NCT02177110
Collaborators
Not Provided
Investigators
Not Provided